Fungal infections in the setting of stem cell transplant ind GVHD are notoriously hard to treat.SOmetimes, infections do nto respond. In some such situations, clinicians empirically combine more than one anti-fungal agents, such as amphotericin and micofungin. In vitro and mouse studies suggest greater efficacy for amphotericin and micofungin combination and favorable distributions, although human studies thus far have focused on comparative efficacies of these two agents, and combination studies are just beginning. Such studies are active, for example, Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis (MAGIC-2), CT00815516.
For Professional version see here